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Abstract: Previous study showed inhibition of RhoA and Rho kinase (ROCK) activity with fasudil could alleviate diabetesinduced cardiac dysfunction partially due to improvement of myocardial fibrosis. However, the effect of fasudil on intracellular calcium cycling and actin remodeling, both of which are important to regulate excitation-contract coupling, is still not fully elucidated. In this study, a diabetic cardiomyopathy model was induced by a single intraperitoneal injection of streptozotocin (STZ) in male Sprague Dawley rats. Diabetic rats were treated with fasudil or placebo for 8 weeks. We found that long-term administration of fasudil, a specific Rho kinase inhibitor, significantly ameliorated diabetesinduced contractile dysfunction both at cellular and whole organ levels. Fasudil-treated rats displayed improved diastolic intracellular calcium ([Ca 2+ ] i ) removal and rescued expression of protein responsible for [Ca 2+ ] i clearance. Furthermore, our study indicated that fasudil treatment normalized the phosphorylation of the PKCβ 2 /Akt pathway in the diabetic heart, which might be the underlying mechanism accounting for the protective effect of fasudil on [Ca 2+ ] i clearance. In addition, compared to the diabetes group, fasudil also normalized the G/ Factin ratio by preventing cofilin phosphorylation and promoted F-actin organization, suggesting a beneficial effect on actin remodeling. These findings indicate the protective effect of fasudil against diabetes-induced cardiac dysfunction via modulation of Ca 2+ handling and actin remodeling. 
